Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
Method for treatment of heart failure
US10059946B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10059946-B2 |
| Application number | US-201615250007-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 29, 2016 |
| Priority date | Dec 3, 2010 |
| Publication date | Aug 28, 2018 |
| Grant date | Aug 28, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating congestive heart failure or chronic heart failure in a patient in need thereof, wherein said congestive heart failure and said chronic heart failure are heart failures induced by mineralcorticoid receptor (MR) activation, comprising administering to the patient a therapeutically effective amount of a neutrophil gelatinase-associated lipocalin (NGAL) antagonist, wherein said NGAL antagonist is an antibody which specifically inhibits the biological activity of NGAL in cardiac cells to treat said congestive heart failure or chronic heart failure induced by MR activation and wherein said antibody is in the form of a pharmaceutical composition.
Assignees
Inventors
Classifications
Compounds having three or more nucleosides or nucleotides · CPC title
Aptamers · CPC title
Antisense · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Special therapeutic applications · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10059946B2 cover?
- The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
- Who is the assignee on this patent?
- Jaisser Frederic, Farman Nicolette, Inst Nat Sante Rech Med
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1135. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).